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Abstract
Background: Self-care is believed to improve heart failure (HF) outcomes, but the mechanisms by which such
improvement occurs remain unclear.
Methods: We completed a secondary analysis of cross-sectional data collected on adults with symptomatic
HF to test our hypothesis that effective self-care is associated with less myocardial stress and systemic
inflammation. Multivariate logistic regression modeling was used to determine if better HF self-care reduced
the odds of having serum levels of amino-terminal pro-B-type natriuretic peptide and soluble tumor necrosis
factor α receptor type 1 at or greater than the sample median. Heart failure self-care was measured using the
Self-care of Heart Failure Index.
Results: The sample (n = 168) was predominantly male (65.5%), and most (50.6%) had New York Heart
Association III HF (mean left ventricular ejection fraction, 34.9% [SD, 14.0%]); mean age was 58.8 (SD,
11.5) years. Self-care management was an independent factor in the model (block χ2 = 14.74; P = .005) after
controlling for pertinent confounders (model χ2 = 52.15; P < .001). Each 1-point increase in self-care
management score (range, 15-100) was associated with a 12.7% reduction in the odds of having levels of both
biomarkers at or greater than the sample median (adjusted odds ratio, 0.873; 95% confidence interval,
0.77-0.99; P = .03).
Conclusion: Better self-care management was associated with reduced odds of myocardial stress and systemic
inflammation over and above pharmacological therapy and other common confounding factors. Teaching HF
patients early symptom recognition and self-care of symptoms may decrease myocardial stress and systemic
inflammation.
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Abstract
Background—Self-care is believed to improve heart failure (HF) outcomes, but the mechanisms
by which such improvement occurs remain unclear.
Methods—We completed a secondary analysis of cross-sectional data collected on adults with
symptomatic HF to test our hypothesis that effective self-care is associated with less myocardial
stress and systemic inflammation. Multivariate logistic regression modeling was used to determine
if better HF self-care reduced the odds of having serum levels of NT proBNP and soluble TNFα
receptor type 1 at or above the sample median. HF self-care was measured using the Self-Care of
Heart Failure Index.
Results—The sample (n=168) was predominantly male (65.5%) and most (50.6%) had NYHA
III HF (mean LVEF= 34.9%±14.0%); mean age was 58.8±11.5 years. Self-care management was
an independent factor in the model (block χ2 =14.74, p=.005) after controlling for pertinent
confounders (model χ2 =52.15, p<.001). Each one-point increase in self-care management score
(range 15–100) was associated with a 12.7% reduction in the odds of having both biomarkers at or
above the sample median (adjusted odds ratio =0.873, 95% CI=0.77–0.99, p=.03).
Conclusion—Better self-care management was associated with reduced odds of myocardial
stress and systemic inflammation over and above pharmacologic therapy and other common
confounding factors. Teaching HF patients early symptom recognition and self-care of symptoms
may decrease myocardial stress and systemic inflammation.
Published in final edited form as:
J Cardiovasc Nurs. 2011 ; 26(4): 321–328. doi:10.1097/JCN.0b013e31820344be.
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Introduction
According to commonly-accepted pathogenic hypotheses, hormones1 and pro-inflammatory
cytokines2 produced in response to heart failure (HF) contribute to progressive deterioration
of cardiac performance. In support of these hypotheses, poor HF outcomes have been linked
to elevated serum levels of biomarkers of myocardial stress and inflammation, including
cardiac hormones3,4 and pro-inflammatory mediators.5,6 In addition to optimal medical
management, engaging in effective self-care may be one way of reducing myocardial stress
and limiting systemic inflammation in patients with HF.7
Self-care of HF involves behaviors that help prevent HF exacerbations such as following
treatment advice (self-care maintenance).8 Importantly, self-care of HF also involves the
decision-making process in which patients evaluate and address HF symptoms when they
occur (self-care management).8 For HF clinicians, teaching and promoting effective self-
care is a core component of disease management.9 Yet, there is limited evidence to support
the assumption that effective HF self-care improves health outcomes.10 A highlight of the
recent American Heart Association scientific statement on promoting HF self-care was the
need to establish mechanisms by which self-care of HF may influence neurohormonal and
inflammatory function.11 Although we have proposed hypothetical mechanisms by which
self-care may influence both processes in the HF population,7 these mechanisms remain
untested.
The purpose of this study was to describe the relationship between participant-reported HF
self-care and serum biomarkers of myocardial stress and systemic inflammation. We
hypothesized that patients who reported better HF self-care would be less likely to have
elevated serum levels of amino terminal pro-B-type natriuretic peptide (NT-proBNP), an
index of myocardial stress,12 and soluble tumor necrosis factor alpha receptor 1 (sTNFR1),
an index of systemic inflammation and marker of HF pathogenesis.12 Using established
prognostic cut-off values for NT-proBNP3 and sTNFR1,6 we tested the influence of HF
self-care on the odds of having serum levels of NT-proBNP and sTNFR1 at or above the
sample median.
Methods
We completed a secondary analysis of cross-sectional data collected at the time of
enrollment in two parent studies13,14 conducted by a single group of HF investigators.
Measures of HF self-care and biomarker data were available on 168 community-dwelling
subjects, all of whom reported having HF symptoms within the past 3 months and did not
have an implanted re-synchronization device. Subjects were recruited from academic
medical centers in the East South Central region of the United States between 2004 and
2008. Data were collected by research staff members who were rigorously trained and
retrained periodically by senior scientists and observed to meet the highest standards in
every aspect of data collection. The parent studies were reviewed and approved by the
institutional review boards at each participating center. Written informed consent was
obtained from all study participants.
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Measurement
Baseline sociodemographic characteristics were measured during enrollment. Age, gender,
and ethnicity were collected using patient interview and medical record review. Height and
weight, measured using a stadiometer and beam scale, were used to calculate body mass
index (BMI). Comorbid conditions were assessed with the interview format of the Charlson
Comorbidity Index.15 A list of 17 comorbid diseases was evaluated with the possible score
ranging from 0 to 30; all participants had a score of at least 1 because all had HF. Clinical
HF characteristics including duration of HF, etiology, and left ventricular ejection fraction
(LVEF) were extracted from the medical record. Functional status was measured using
clinician-rated New York Heart Association (NYHA) functional class obtained through
chart review.
HF self-care was measured by participant-report using the Self-Care of Heart Failure Index
(SCHFI) v.4.8 In most cases, SCHFI data were collected through interview; some
participants opted to complete the SCHFI themselves. The SCHFI contains 15 items
measured on a four-point Likert scale and captures self-care maintenance (adherence
behaviors that maintain physiologic homeostasis and prevent HF symptoms and
exacerbations), self-care management (symptom evaluation, symptom treatment, and
treatment evaluation behaviors), and self-care confidence (perceived ability to engage in
each phase of the self-care management process). HF patients were asked to think about the
past 3 months when completing the SCHFI. Scores on each of these three SCHFI scales
were standardized to range from 0–100, with higher scores indicating better self-care.
Reliability (alpha) of the SCHFI v.4 maintenance, management, and confidence scores have
been reported previously as 0.56, 0.70, and 0.82 respectively; construct validity of the
SCHFI scales also has been supported by confirmatory factor analysis.8
Serum samples were collected during enrollment into the parent studies. Enzyme
immunoassays kits were used to determine serum concentrations of NT-proBNP (ALPCO
Diagnostics, Salem NH), and sTNFR1 (R &D Systems, Minneapolis MN). All samples were
run in duplicate with an average inter-sample coefficient of variation (CV) < 2%; samples
with a CV ≥ 10% were repeated. Serum levels of NT-proBNP were quantified in fmol/mL,
and serum levels of sTNFR1 were quantified in pg/ml. We used NT-proBNP and sTNFR1,
instead of B-type natriuretic peptide and tumor necrosis factor alpha, respectively, because
of the previously established prognostic cutoff values of these biomarkers in prior research.
3,6
Myocardial Stress and Systemic Inflammation
Our interest focused on the influence of HF self-care on the odds of having higher levels of
both NT-proBNP and sTNFR1 for four reasons. First, using multiple markers of HF
pathogenesis improves the prediction of poor cardiovascular outcomes.16 Second, there is
significant intra-individual variability in serum levels of both NT-proBNP17 and sTNFR118
in persons with HF that interjects random error and can limit estimates of association,19
especially with cross-sectional data. Third, according to the most recent categorization of
HF biomarkers, sTNFR1 is an index inflammation and HF pathogenesis,12 whereas NT-
proBNP is considered an index of myocardial stress12 and should only be used as a
confirmatory biomarker.20 Thus, fulfilling a fundamental requirement for effective multiple
biomarker strategies21 and a recommendation for biomarker profiling in patients with HF,
12 NT-proBNP and sTNFR1 represent distinct classes of biomarkers and reflect separate
processes. Fourth and most importantly, we have hypothesized previously that HF self-care
influences health outcomes through multiple cardioprotective means concurrently.7
Lee et al. Page 3
J Cardiovasc Nurs. Author manuscript; available in PMC 2012 July 1.
Statistical Analysis
All analyses were performed using Stata/MP version 10.0 (StataCorp, College Station, TX).
Statistical significance was predetermined at p < .05. Continuous normally distributed data
are expressed as mean values (±SD). Non-normally distributed data (i.e. continuous
biomarker data) are expressed as the median [25th, 75th percentile]. Multivariate logistic
regression modeling was used to determine if better self-care reduced the odds of patients
having levels of both NT pro-BNP and sTNFR1 above the sample median. For reference,
we also present modeling of each biomarker separately. Median, as opposed to mean, values
were used based on the work of Gardner et al.3 and Ueland et al.,6 and due to the skewed
distribution of both biomarkers.
Rationale for Model Covariates
Patient characteristics of age, gender, BMI, and Charlson comorbidity category (low,
medium, high), and HF characteristics of LVEF, NYHA functional class, and HF etiology
were included in the first block of the model. Levels of NT-proBNP increase with age22 and
are higher in women.22 On average, plasma levels of NT-proBNP are inversely proportional
to values of BMI23 and vary considerably by comorbid conditions.24 Plasma levels of NT-
proBNP are inversely proportional to values of LVEF25 and directly proportional to NYHA
functional class.25 Levels of sTNFR1 vary significantly by HF etiology.26 We also
controlled for commonly prescribed HF medications with neurohomonal blocking and/or
anti-inflammatory effects (β-adrenergic blockers,27 angiotensin converting enzyme [ACE]
inhibitors28 or angiotensin II receptor blockers [ARB]s,29 and cholesterol lowering agents.
30
The Additive Influence of Heart Failure Self-Care
To determine the additive influence of measures of HF self-care in explaining the odds of
having higher levels of both biomarkers, the three SCHFI scales (continuous data) were
added to the second block of the model. Based on observed nonlinear bivariate relationships
between self-care management and both biomarkers (data not shown), we also tested the
quadratic effect of self-care management. Using the most common method of testing for a
nonlinear relationship,31 we included both the SCHFI self-care management score and self-
care management score-squared as independent variables in the second block of the model.
The influence of each model block was assessed by evaluating the significance of the block
and overall model χ2. Model fit was assessed using model χ2, Nagelkerke psedo-R2, and
correct classification rates. The significance of individual characteristics was evaluated by
calculating adjusted odds ratios (OR) with 95% confidence intervals (CI).
Results
The sample (n = 168) was predominantly male, Caucasian, and in middle adulthood (Table
1). Most (58.4%) had at least a moderate Charlson comorbidity score and HF of ischemic
origin. Coefficient alpha for the SCHFI scales for patients included in this analysis were .68
(maintenance), .89 (management), and .86 (confidence). Average levels of self-care were
generally low, with mean values of each SCHFI scale below the previously established cut-
point of adequacy (70 out of 100 points).32 The median serum level of NT-proBNP was
582.8 fmol/mL and the median serum level of sTNFR1 was 1710.1 pg/mL.
Full multivariate models are presented in Table 2. Only participant age and self-care
management score consistently influenced the likelihood of having higher biomarker levels
across the three models. That is, older age was associated with increased odds of having
higher NT-proBNP, higher levels of sTNFR1, and higher levels of both NT-proBNP and
sTNFR1. Pointedly, although not consistently significant, better self-care management was
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associated with lower odds of higher biomarker levels. Moreover, the relationship between
self-care management and the odds higher biomarker levels was consistently nonlinear.
A minority of subjects (n=37, 22.0%) had serum levels of both NT-proBNP and sTNFR1
above the sample median. Patient characteristics (age, gender, BMI, and Charlson
comorbidity category), and HF characteristics (LVEF, NYHA, etiology, and HF
medications) added significantly to the model (block χ2 = 37.41, p < .001). In the second
block, the three self-care scales and the quadratic effect of self-care management also added
significance to the model (block χ2 = 14.74, p = .005); the full model was significant (χ2 =
52.15, p < .001; pseudo R2 = 41%; 86.9% of subjects correctly classified).
In the full multivariate model of both biomarkers, for every one-year difference in patient
age there was a 10% change in adjusted odds of having higher levels of both biomarkers.
The adjusted odds of having both biomarkers at or above the median were increased by
110% and 220% for medium and high comorbidity categories respectively. In addition, self-
care management and the quadratic effect of self-care management were significant
determinants of having levels of both biomarkers at or above the sample median. This
finding indicated that the nonlinear relationship between self-care management and
biomarker levels was also prominent in the model. Each one-point difference in self-care
management score was associated with a 12.7% change in the odds of having both
biomarkers at or above the sample median. However this relationship was nonlinear,
meaning that there was reduction in the adjusted odds of having both biomarkers above the
sample median for every one-point increase in self-care management score up to 70 (sample
range from 15–100) (Figure 1). In contrast, and because of the nonlinear relationship, the
adjusted odds of having both biomarkers above the sample median tended to be higher for
every increase in self-care management score above 70. This effect was more prominent in
the 6.6% of patients reporting the highest levels of self-care management.
Discussion
To the best of our knowledge, this is the first clinical investigation of the relationship
between participant-reported self-care and serum biomarkers of myocardial stress and
systemic inflammation in persons with HF. In support of our hypothesis, our most important
finding was that in this sample of 168 patients with HF, better decision-making in response
to HF symptoms (self-care management) was associated with reduced odds of having higher
levels of NT-proBNP and sTNFR1. Interestingly and because of a nonlinear relationship,
patients who reported the highest levels of self-care management had a trend toward
increasing odds of having higher levels of both biomarkers.
The Influence of Heart Failure Self-Care Management
Our previous work has provided evidence that patients who reported better HF self-care
management had a reduced risk of one-year mortality or hospitalization compared with
those who practice poor self-care management.33 We have hypothesized previously that
mechanisms through which effective HF self-care practices complement optimal medical
management include neurohormonal and inflammatory homeostasis.7 In patients with HF,
higher serum levels of NT-proBNP generally reflect greater synthesis and secretion of BNP
due to myocardial distension and stress.34,35 Higher levels of sTNFR1 reflect elevated
levels of active TNFα36 triggered by direct antigenic stimulation,37 endothelial disruption,
38 and direct hemodynamic stress.39 Patients with HF may be able to manage their
symptoms by making small adjustments to fluid or sodium intake or by taking low-dose
diuretics7 and thereby limit the risk of reactive increases in neurohormonal activation that
can occur with large changes in sodium intake40 or high-dose diuretics.41 Self-management
of congestion may also limit the translocation of gut bacteria into the blood stream42 and
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help limit wall tension that impedes myocardial perfusion43 and causes hemodynamic
stress, tissue ischemia, and inflammation in HF.
We also found that the relationship between self-care management and HF biomarkers was
nonlinear. For the 70% of the sample with self-care management scores equal to or below
70, incremental improvements in self-care management were associated with significantly
lower odds of having both biomarkers above the sample median holding other factors
constant (Figure 1). For the remaining 30% of the sample, and particularly for the 7% of
patients reporting very high levels of self-care management, incremental increases in self-
care management were associated with an increase in the odds of having higher levels of
both biomarkers. While the odds of having both biomarkers above the sample median for
patients reporting the best self-care management did not approximate the high likelihood
observed in patients who reported the poorest self-care management, this observation is
quite intriguing.
We postulate two main reasons why patients who reported the highest levels of self-care
management were more likely to have higher biomarker levels. First, signs and symptoms of
HF progression and/or cytokine-induced symptoms like malaise and general aching44,45
may drive patients to become more engaged in self-care (Figure 2). Lorig and Holman46
argue that by nature, self-care management is problem-based. That is, HF symptoms may
indicate changes in underlying HF pathogenesis about which patients must make decisions
and engage in problem-solving behavior. In previous research, HF patients who experienced
more symptoms also were more engaged in HF self-care maintenance behaviors.47,48 In
addition to driving better self-care maintenance, HF symptoms that are not addressed
effectively may persist or become more burdensome and serve as a “wake up call” for
patients to develop skill in detecting and managing HF symptoms earlier in their
development or to try additional strategies to ameliorate symptoms.47
Despite the appeal of this seemingly intuitive explanation, however, there are two empirical
gaps that remain problematic. First, results from previous researchers suggest that HF
symptoms are only loosely related to measures of pathogenesis. For example, Rector et al.49
observed that measures of HF pathogenesis, including LVEF, BNP, jugular venous
distension, rales, peripheral edema, systolic blood pressure, creatinine, and hemoglobin,
were not strongly related to HF symptoms. In addition, Shah et al.50 reported that changes
in hemodynamic measures do not predict concomitant changes in underlying HF
pathogenesis. These results demonstrate that there is considerable dissociation between
indices of HF pathogenesis and HF symptoms. Others also have found no difference in self-
care between patients who experience consistent or inconsistent symptoms over time.51
Thus, assumptions about the link between HF pathogenesis and HF symptoms, and the link
between HF symptoms and improved self-care management are not well supported. As the
measurement of self-care management in particular is relatively new, very little is known
about the determinants of this aspect of HF self-care.
The second possible explanation of why patients who reported the highest levels of self-care
management were more likely to have higher biomarker levels is that HF pathogenesis may
become refractory even to the best self-care management. That is, perhaps HF has
progressed beyond the effectiveness of even expert level decision-making, experience, and
skill in evaluating and ameliorating HF symptoms. Instead, increased involvement of
clinical experts and advanced monitoring and treatment therapies may be needed to decrease
myocardial stress and systemic inflammation and minimize the risk of the associated clinical
outcomes. Zambroski articulated the importance of promoting self-care of HF even in
palliative care settings.52 But, the progressive nature of this multisystem disorder will at
some point dominate over self-care in all persons with HF.
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Morrow and Lemos53 argue that cardiovascular biomarkers must have clinical application,
including risk stratification or monitoring of therapeutic response. In previous HF research,
levels of NT-proBNP above the sample median have been associated with a greater risk of
mortality,3,4,54 urgent ventricular assist device implantation, and urgent heart
transplantation.3,4 Patients with higher levels of sTNFR1 also have an increased risk of
mortality.5,6 Thus, patients with levels of NT-proBNP and sTNFR1 above the sample
median have greater myocardial stress and systemic inflammation and are at-risk for poor
HF outcomes. Importantly, having higher levels of both biomarkers also may indicate
ineffectiveness of HF self-care. That is, HF progression may be refractory to self-care or
these patients may not be engaged sufficiently in self-care management. Either way, patients
with elevated levels of multiple HF biomarkers are a group primed for aggressive
intervention and may require strategies beyond those focused on promoting self-care.
Other Factors and Heart Failure Biomarkers
Patient age was significant in our multi-marker model, confirming the results of previous
research.22,55 Comorbidity category also was a determinant of having higher levels of both
biomarkers confirming the results of others.24 Although confidence in self-care was helpful
in explaining the nonlinear relationship between self-care management and health outcomes
in our previous research,56 self-care confidence was not a factor in explaining the odds of
having high levels of both biomarkers. Similarly, self-care maintenance, which most view as
analogous to treatment adherence, was not a factor in our model. Therefore, we strongly
recommend that the decision-making process of self-care management be measured and
included as a determinant of HF biomarkers and health outcomes in future research, not just
self-care maintenance or treatment adherence behaviors.
Strengths and Limitations
This was a secondary analysis of cross-sectional study data. Thus, it is not possible to make
inferences about temporal aspects of the relationship between self-care management and
circulating biomarkers.57 Although we controlled for pertinent confounders, other factors,
such as the influence of the family or other caregivers, could influence the relationship
between HF self-care and the biomarkers studied. In accordance with our objective, self-care
was measured by participant-report. Although there are limitations to collecting data on self-
care via participant report, the SCHFI is the only available instrument that measures HF self-
care management.58 Follow-up studies in which self-care behaviors are measured
objectively may either support or refute our results. The relatively young age and high BMI
of the sample makes it more difficult to extend inferences from these results to all other HF
patient populations. Lastly, as we studied the relationship between self-care and circulating
biomarkers in self-identified African American and Caucasian persons with HF, our findings
may not be supported in all cultural, ethnic, or racial groups. Future prospective and
experimental studies are needed to gain more insight into the complex relationship between
HF self-care and these biomarkers and to determine in whom HF self-care is most effective
in reducing myocardial stress and systemic inflammation.
Conclusion
In summary, incremental increases in decision-making about HF symptoms and treatment
were associated with lower odds of having higher levels of both NT-proBNP and sTNFR1,
indicating less extensive myocardial stress and systemic inflammation. For patients
reporting the best self-care management, however, there was a trend favoring greater odds of
higher biomarker levels. This pattern may suggest that HF symptoms drive engagement in
self-care management or that for some patients HF pathogenesis is refractory to even the
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most effective self-care practices. Patients with higher levels of multiple HF biomarkers
need innovative intervention and concentrated future research.
What is New/ Summary and Implications
• Patients with heart failure (HF) who reported better decision-making about HF
symptoms and treatment were less likely to have levels of biomarkers of
myocardial stress and systemic inflammation shown by others to be associated
with associated greater risk of mortality, urgent ventricular assist device
implantation, and urgent heart transplantation.
• Effective HF self-care practices related to symptom recognition, treatment, and
treatment evaluation, may complement optimal medical management in
maintaining neurohormonal and inflammatory homeostasis.
• Evaluating, teaching, and promoting effective self-care behaviors in persons
with HF are evidence-based practices.
• Self-care maintenance, which most view as analogous to treatment adherence,
was not a factor in our model, and we strongly recommend that the decision-
making process of self-care management be measured and included as a
determinant of HF biomarkers and health outcomes in future research.
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Figure 1. The Influence of Self-Care Management on the Adjusted Odds of Having Levels of NT-
proBNP and sTNFR1 Above the Sample Median
The relationship between self-care management and levels of biomarkers of myocardial
stress and systemic inflammation varied across levels of self-care management. Horizontal
dashed line indicates neutral odds; for 69.6% of the sample, better self-care management
was associated with lower odds of having levels of both biomarkers above the sample
median. For the remaining 30.4% (those with self-care management scores of 70 or above),
higher levels of self-care management were associated with increasing trend in the odds of
having higher levels of both biomarkers. Results shown are adjusted for the influence of age
(sample mean), gender (female), body mass index (sample mean), Charlson comorbidity
category (low), left ventricular ejection fraction (sample mean), New York Heart
Association functional class (I), non-ischemic etiology, and commonly prescribed heart
failure medications.
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Figure 2. Two Potential Reasons Why Patients Who Reported the Best Self-Care Had Higher
Levels of Biomarkers of Myocardial Stress and Systemic Inflammation
1) Signs and symptoms of HF progression and/or cytokine-induced symptoms may serve as
a “wakeup call” and drive patients to engage in better self-care management. 2) Heart failure
pathogenesis may be refractory to even the most effective self-care practices (e.g. self-care
is not enough), and the intervention of heart failure expert clinicians is what is needed to
reduce myocardial stress and systemic inflammation.
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Table 1
Sociodemographic and Clinical Characteristics of the Sample (N=168)
ACE=angiotensin converting enzyme, ARB=angiotensin II receptor blocker, NT-proBNP=amino terminal pro
B-type natriuretic peptide, NYHA=New York Heart Association, SCHFI=Self-Care of Heart Failure Index,
SD=standard deviation, sTNFR1=soluble tumor necrosis factor alpha receptor type 1.
Variable Mean ± SD, n (%), or Median
[25th,75th percentile]
Patient Characteristics:
  Age (years) 58.8 ± 11.4
  Female 58 (34.5%)
  Ethnicity:
    African America 30 (17.9%)
    Caucasian 136 (81.0%)
    Mixed 2 (1.2%)
  Education:
    < High school graduate 35 (20.8%)
    High school graduate 50 (29.8%)
    Some college 42 (26.2%)
  Associate degree or greater 38 (22.6%)
  Body Mass Index (kg/m2) 32.8 ± 7.1
  Charlson Comorbidity Category:
    Score of 1 or 2 (low) 70 (41.7%)
    Score of 3 or 4 (medium) 48 (28.6%)
    Score of 5 or more (high) 50 (29.8%)
Heart Failure Characteristics:
  Left Ventricular Ejection Fraction (%) 34.8 ± 14.0
  NYHA Functional Class:
    Class I 5 (3.0%)
    Class II 49 (29.2%)
    Class III 85 (50.6%)
    Class IV 29 (17.3%)
  Heart Failure Etiology:
    Ischemic 88 (52.4%)
    Idiopathic 32 (19.0%)
    Hypertensive 18 (10.7%)
    Other (known) 30 (17.9%)
  Prescribed a β-blocker (%) 148 (88.1%)
  Prescribed an ACE or ARB (%) 135 (80.4%)
  Prescribed a cholesterol lowering agent (%) 113 (67.3%)
Self-Care of Heart Failure:
  SCHFI Maintenance Score 63.0 ± 16.2
  SCHFI Management Score 61.1 ± 19.2
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Variable Mean ± SD, n (%), or Median
[25th,75th percentile]
  SCHFI Confidence Score 64.6 ± 15.0
Biomarkers:
  NT-proBNP (fmol/mL) 582.8 [431.7,845.6]
      range 59.9 to 3301.5
  sTNFR1 (pg/mL) 1710.1 [1390.8,2234.5]
      range 795.3 to 9718.0
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Table 2
Adjusted Odds (and 95% CI) of Having Heart Failure Biomarkers at or Above the
Sample Median: Self-Care Management and Other Factors Retaining Individual
Significance
All results (displayed in adjusted odds ratios and 95% confidence intervals) are adjusted for age, gender, body
mass index, left ventricular ejection fraction, New York Heart Association functional class, heart failure
etiology, prescription of a β-adrenergic blocker, prescription of an angiotensin converting enzyme inhibitor or
angiotensin receptor blocker, prescription of a cholesterol lowering agent, Charlson Comorbidity Index
Category, and Self-Care of Heart Failure Index maintenance and confidence scale scores.
NT-proBNP sTNFαR1 NT-proBNP & sTNFαR1
Age 1.051 (1.009–1.095) 1.077 (1.035–1.121) 1.104 (1.050–1.159)
Body Mass Index 0.922 (0.864–0.984) 1.080 (1.016–1.149) -
NYHA Class - 2.044 (1.113–3.754) -
ACE or ARB - 0.218 (0.074–0.641) -
Charlson Category - 1.754 (1.069–2.878) 2.109 (1.163–3.824)
SC Management 0.908 (0.803–1.032)† 0.945 (0.836–1.067)† 0.873 (0.771–0.988)
SC Management ×
SC Management *
1.001 (1.0001–1.002) 1.001 (1.000–1.002) 1.001 (1.0003–1.002)
Model Fit:
      χ2 33.06; p=.003 58.52; p<.001 52.15; p<.001
  Nagelkerke R2 .299 .404 .410
    CCR 68.5% 76.0% 86.9%
Abbreviations ACE= angiotensin converting enzyme inhibitor, ARB= angiotensin receptor blocker, CCR = correct classification rate,
CI=confidence interval, NT-proBNP=amino terminal pro B-type natriuretic peptide, NYHA= New York Heart Association, SC=self-care,
sTNFR1=soluble tumor necrosis factor alpha receptor type 1.
*
quadratic function of self-care management score.
†
did not retain individual significance.
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